Sodium- myo -inositol cotransporter-1, SMIT1, promotes cardiac hypertrophy and fibrosis induced by pressure overload in mice
Cardiovascular Research · 2026
DOI: 10.1093/cvr/cvag040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, 2026. Verfasst von Alice Marino und 18 weiteren Autor:innen. Beteiligte Einrichtung: Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Av. Hippocrate 55, Brussels 12…. Hauptthemen laut MEDLINE: Cardiomegaly, Symporters, Ventricular Remodeling. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds de Recherche du Quebec, Fonds National de la Recherche Scientifique, FRS-FNRS.
Abstract (Originalsprache)
Aims
Recent clinical studies have reported that myo-inositol is consistently elevated in plasma of patients with heart failure (HF), yet its role in cardiac dysfunction remains poorly understood. Myo-inositol is specifically transported into cells by the sodium-myo-inositol co-transporter-1 (SMIT1), a member of the sodium-glucose co-transporter (SGLT) family expressed in the heart. While myo-inositol is essential for phosphoinositide signalling, osmoregulation, and metabolic homeostasis, dysregulation of SMIT1-mediated myo-inositol transport may contribute to key pathological mechanisms in HF. This study aims to elucidate the role of SMIT1 in the failing heart, especially during left ventricular remodelling that precedes it. Methods and results We used a mouse model of pressure overload induced by transverse aortic constriction in wild-type (WT) mice and mice lacking SMIT1 (Smit1−/−), and primary cultured cardiomyocytes. By combining molecular, structural and functional studies, RNA-sequencing, and calcium measurements, we demonstrate the contribution of myo-inositol and SMIT1 to pathological hypertrophy and the progression towards HF. We found that in comparison to WT controls, Smit1−/− mice were protected against aortic banding induced systolic dysfunction, cardiac fibrosis and hypertrophy. This hypertrophic response was driven by SMIT1 expression in cardiomyocytes, where it favours intracellular myo-inositol and Na+ entry, leading to inositol 1,4,5-trisphosphate (IP3)- and Ca2+-dependent pro-hypertrophic signalling. Following haemodynamic stress, deletion of SMIT1 significantly altered IP3/calcium effectors, including Carabin, which modulates cardiac hypertrophy through inhibition of the calcineurin/nuclear factor of activated T-cell and Ras/ERK1/2 pathways.
Conclusion
This work provides important insights into the role of myo-inositol and SMIT1 in cardiomyocytes. We demonstrate that SMIT1 is a key driver of pathological hypertrophy by inducing an IP3/Ca2+-dependent pro-hypertrophic transcriptional reprogramming in cardiomyocytes. These findings identify SMIT1 as a promising therapeutic target for preventing or treating pathological cardiac hypertrophy and HF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Av. Hippocrate 55, Brussels 1200, Belgium.
- Division of Cardiology, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.
- Laboratory of Experimental Cardiology, Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.
- Centre de technologies moléculaires appliquées, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium.
- Department of Anesthesiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
- Institut des Maladies Métaboliques et Cardiovasculaires, Université de Toulouse, UMR-1297 Inserm, Toulouse, France.
ORCID-Profile: Alice Marino, Sylvain Battault, Greet Kerckhofs, Luc Bertrand, Sandrine Horman
Förderung
- Fonds de Recherche du Quebec
- Fonds National de la Recherche Scientifique
- FRS-FNRS
- Wallonia-Brussels Federation
- FRQ-FNRS
- Action de Recherche Concertée de la Communauté Wallonie-Bruxelles, Belgium
- Research Foundation Flanders
- ASBL Jean Degroof-Marcel Van Massenhove funding
Zitieren
APA
Marino, A., Cumps, J., Guilbert, L., Geiser, A., Baufays, C., Ginion, A., Ferté, L., Battault, S., De Matos, F., Ambroise, J., Zuurbier, C. J., Lezoualc'h, F., Pestiaux, C., Pyka, G., Kerckhofs, G., Roderick, H. L., Bertrand, L., Horman, S., & Beauloye, C. (2026). Sodium- myo -inositol cotransporter-1, SMIT1, promotes cardiac hypertrophy and fibrosis induced by pressure overload in mice. Cardiovascular Research. https://doi.org/10.1093/cvr/cvag040
Vancouver
Marino A, Cumps J, Guilbert L, Geiser A, Baufays C, Ginion A, et al. Sodium- myo -inositol cotransporter-1, SMIT1, promotes cardiac hypertrophy and fibrosis induced by pressure overload in mice. Cardiovascular Research. 2026. doi:10.1093/cvr/cvag040
BibTeX
@article{Marino2026,
author = {Marino, Alice and Cumps, Julien and Guilbert, Laura and Geiser, Angéline and Baufays, Claire and Ginion, Audrey and Ferté, Laura and Battault, Sylvain and De Matos, Fiona and Ambroise, Jerome and Zuurbier, Coert J and Lezoualc'h, Frank and Pestiaux, Camille and Pyka, Grzegorz and Kerckhofs, Greet and Roderick, H Llewelyn and Bertrand, Luc and Horman, Sandrine and Beauloye, Christophe},
title = {Sodium- myo -inositol cotransporter-1, SMIT1, promotes cardiac hypertrophy and fibrosis induced by pressure overload in mice},
journal = {Cardiovascular Research},
year = {2026},
doi = {10.1093/cvr/cvag040}
}
EUVIMED